Patients with pathological confirmed non-small cell lung cancer with no standard treatment are enrolled. The patients fails in previous at least 2 lines of chemotherapy and 1 line of targeted therapy where applicable. This is a prospective exploratory trial. Patients' rebiopsy tumor tissues are subsequent to whole exosome sequencing and possible neoantigens are identified. DC is in vitro primed with synthesized peptides. Both adverse events and responses are recorded.
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
pathologically confirmed non-small cell lung cancer
failed in previous standard chemotherapy and targeted therapy
anticipated life time \> 3month
Karnofsky performance status 0-1
rehabilitate from previous therapy
adequate organ functions
You may not be if
mixed histological types
tumor emergency
abnormal coagulation condition
contagious diseases, such as hepatitis B virus, hepatitis C virus, human immunodefficiency virus, tuberculosis infection
concomitant tumors
immunological co-morbidities
Clareo Health | Personalized DC Vaccine for Lung Cancer
